1. Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples
- Author
-
Johannes A. Hainfellner, Martin Filipits, Sabine Spiegl-Kreinecker, Anna S. Berghoff, Christopher L. Corless, Andrew Kohlway, Michael Bates, Kriszten Kocmond, Edwin W. Lai, Matthias Preusser, and Jodi Weidler
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Concordance ,Polymerase Chain Reaction ,DNA methyltransferase ,Young Adult ,Internal medicine ,medicine ,Humans ,Child ,Promoter Regions, Genetic ,DNA Modification Methylases ,neoplasms ,Aged ,Aged, 80 and over ,GeneXpert MTB/RIF ,Brain Neoplasms ,business.industry ,Tumor Suppressor Proteins ,Reproducibility of Results ,Promoter ,General Medicine ,Methylation ,DNA Methylation ,Middle Aged ,medicine.disease ,digestive system diseases ,DNA Repair Enzymes ,DNA methylation ,Pyrosequencing ,Biological Assay ,Female ,Glioblastoma ,business - Abstract
Background/aim To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. Materials and methods The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay. Results The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively). Conclusion Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.
- Published
- 2020
- Full Text
- View/download PDF